RNA Sequencing Services Market Report 2026

The rna sequencing services market size has grown rapidly in recent years. It will grow from $3.99 billion in 2025 to $4.44 billion in 2026 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to increasing genomic research funding, expansion of academic and government research initiatives, growing use of sequencing in basic biology studies, declining cost of sequencing technologies, improved availability of sequencing service providers.

The rna sequencing services market size is expected to see strong growth in the next few years. It will grow to $6.38 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to rising adoption of precision medicine approaches, increasing demand for transcriptomic data in diagnostics, expansion of pharmaceutical r&d activities, growing integration of ai-driven data analytics, increasing outsourcing of sequencing services. Major trends in the forecast period include increasing demand for high-throughput transcriptomic analysis, growing adoption of ngs-based rna sequencing, expansion of bioinformatics-integrated sequencing services, rising use of rna sequencing in clinical research, enhanced focus on data accuracy and reproducibility.

The increasing demand for personalized medicine is playing a significant role in driving the growth of the RNA sequencing services market. Personalized medicine involves customizing medical treatments based on individual characteristics such as genetic makeup, lifestyle, and environmental factors to improve treatment effectiveness and reduce adverse effects. The rising demand for personalized medicine is supported by its ability to deliver more precise therapies, advances in genomic technologies, growing disease complexity, and favorable regulatory frameworks. RNA sequencing services support personalized medicine by enabling the identification of disease subtypes, discovery of biomarkers, detection of therapeutic targets, prediction of treatment responses, and monitoring of disease progression and treatment outcomes. By leveraging RNA sequencing technologies, personalized medicine approaches can deliver targeted and effective therapies tailored to the unique molecular profiles of individual patients. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the Food and Drug Administration approved 16 novel personalized therapies for rare disease patients in 2023, compared to six approvals in 2022. These newly approved personalized treatments included seven cancer therapies and three treatments for other diseases and conditions. Thus, the growing demand for personalized medicine is fueling the growth of the RNA sequencing services market going forward.

Major companies operating in the RNA sequencing services market are emphasizing automation to minimize human error and improve operational efficiency, particularly through the development of advanced next-generation sequencing (NGS) assays. RNA next-generation sequencing (RNA-seq) assays are advanced genomic tools used to analyze the complete transcriptome of biological samples with high accuracy and depth. For instance, in June 2023, Tempus, a US-based precision medicine technology company, launched its standalone RNA next-generation sequencing assay, Tempus xR. Designed for solid tumors, this assay delivers comprehensive transcriptome analysis, identifying clinically relevant gene fusions across more than 100 targeted genes, as well as detecting altered splicing events such as MET Exon 14 and EGFRvIII. Tempus has traditionally integrated RNA and DNA sequencing within its xT broad-panel assay, but the introduction of xR allows clients to order RNA and DNA tests independently or together, with optional integration of Tempus algorithm-based analyses. This solution addresses the needs of clinicians focused on RNA fusions or splicing abnormalities, as well as researchers, healthcare providers, and biopharmaceutical companies seeking detailed RNA sequencing insights from existing samples.

In January 2024, Parse Biosciences, a US-based life sciences company, acquired Biomage Ltd. for an undisclosed amount. Through this acquisition, Parse Biosciences aims to strengthen its single-cell RNA sequencing data analysis capabilities, enabling customers to achieve deeper biological insights and faster data interpretation for genomic research and precision medicine applications. Biomage Ltd. is a UK-based company specializing in RNA sequencing data analysis and tools that support advanced genomic research and personalized medicine initiatives.

Major companies operating in the rna sequencing services market are Thermo Fisher Scientific Inc., Illumina Inc., Qiagen NV, BGI Genomics Co Ltd, Azenta Inc., Novogene Co Ltd, Genewiz Inc., Diagenode LLC, CD Genomics, CeGaT GmbH, Lexogen GmbH, BaseClear BV, Active Motif Inc., Microsynth AG, Genomax Technologies Pte Ltd, Creative Biogene, SeqMatic LLC, Genohub Inc., Otogenetics, LC Sciences, Admera Health, Arraystar Inc., IGA Technology, Yaazh Xenomics, Novaseq Services Ltd.

North America was the largest region in the RNA sequencing services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rna sequencing services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rna sequencing services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the RNA sequencing services market by increasing costs of imported sequencing reagents, consumables, laboratory instruments, and advanced bioinformatics hardware. Research institutions and service providers in North America and Europe are most affected due to reliance on imported sequencing platforms, while Asia-Pacific faces cost pressure on reagent and equipment imports. These tariffs are raising operational costs and affecting service pricing structures. However, they are also encouraging local manufacturing of sequencing consumables, regional equipment assembly, and strengthening domestic life sciences supply chains.

The rna sequencing services market research report is one of a series of new reports that provides rna sequencing services market statistics, including rna sequencing services industry global market size, regional shares, competitors with a rna sequencing services market share, detailed rna sequencing services market segments, market trends and opportunities, and any further data you may need to thrive in the rna sequencing services industry. This rna sequencing services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

RNA sequencing is a high-throughput technique used to examine the presence and abundance of RNA molecules within a sample, offering valuable insights into gene expression levels and transcriptomic activity. It is applied to investigate gene expression patterns and regulatory mechanisms involved in various biological processes, including development, disease, and responses to external stimuli.

The main types of RNA sequencing services include ribosomal RNA (rRNA), transfer RNA (tRNA), and long non-coding RNA (lncRNA) sequencing. Ribosomal RNA (rRNA) sequencing focuses on analyzing RNA molecules that form key components of ribosomes, which are essential for protein synthesis within cells. These services utilize different sequencing approaches, including next-generation sequencing and others, and are used across multiple application areas such as research and diagnostics. End users include academic and government institutes, research centers, hospitals and clinics, pharmaceutical and biotechnology companies, and others.

The RNA sequencing services market includes revenues earned by offering sequencing services for RNA analysis, encompassing sample preparation, sequencing, data analysis, and interpretation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.